A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing
Fig 5
Drug-protein interaction after docking.
A. Nucleoprotein-Bictegravir interaction, B. Nucleoprotein-Nebivolol interaction, C. PL Pro-Cilostazol interaction, and D. PL Pro-Elvitegravir interaction. Drugs are in orange while the proteins are labelled in blue and the residues interacting with the drugs are highlighted in red. The contacts are shown in yellow.